NZYM B Novozymes A/S Class B

Initiation of share buyback program

Initiation of share buyback program

On March 5, 2025, Novonesis will initiate a share buyback program as announced in Company Announcement No. 3 of February 26, 2025. Under the program, Novonesis will buy back B shares worth up to EUR 100 million in total during the remainder of 2025, corresponding to around 1.7 million B shares at the current share price. The program is contingent upon no major strategic initiatives being decided upon that will require a significant amount of capital.

The shares acquired in the program will be used to meet obligations arising from employee share-based incentive programs.

The maximum number of shares to be purchased by the company per daily market session will be equivalent to no more than 25% of the average volume of shares in the company traded on NASDAQ OMX Copenhagen during the preceding 20 business days. The program will run in accordance with the European Commission Regulation (EU) No. 596/2014 of 16 April 2014 (the "Market Abuse Regulation"), and the European Commission Delegated Regulation (EU) No. 1052/2016 of 8 March 2016 (the “Safe Harbour Regulation”).

Attachment



EN
05/03/2025

Underlying

NZYM BNovozymes A/S Class B

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Novozymes A/S Class B

 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

November 21, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Trading by management and close relations of management

Trading by management and close relations of management Please read the full announcement in PDF Attachment

November 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Major shareholder announcement

Major shareholder announcement Please read the full announcement in PDF Attachments

November 7, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

Novonesis delivered 8% organic sales growth in the first nine months o...

Novonesis delivered 8% organic sales growth in the first nine months of 2025 Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards.  COPENHAGEN, Denmark – November 6, 2025. Novonesis delivered 8% organic sales growth in the first nine months of 2025. Full-year outlook is narrowed upwards to 7-8%, previously 6-8%. Ester Baiget, President & CEO:  "I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability. Our performance was strong across all sales areas and i...

November 6, 2025 1 EN
 PRESS RELEASE
Free
NZYM B Novozymes A/S C...

8% organic sales growth after first nine months. Full-year organic sal...

8% organic sales growth after first nine months. Full-year organic sales growth narrowed upwards. Ester Baiget, President & CEO: ”I am pleased with our performance in the first nine months, where we delivered 8% organic sales growth with solid profitability and cash flow. Our performance was strong across all sales areas and in Emerging and Developed Markets. We delivered 37.3% adjusted EBITDA margin, despite significant currency headwinds, demonstrating the strength and resilience of our business model. Following a robust nine-months performance including favorable timing in the third quar...

November 6, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch